Year: 2025

Categories : Gastrointestinal NeurologyTags : Leave a comment

Could the Key to IBS Treatment Lie in the Brain?

On By ModernMedia
Irritable bowel syndrome. Credit: Scientific Animations CC4.0

Although irritable bowel syndrome (IBS) affects about a tenth of the global population, the underlying causes and mechanisms of IBS remain unclear and thus treatments focus on symptom management. At Tokyo University of Science (TUS), Japan, Professor Akiyoshi Saitoh and his research group have spent the past decade exploring this topic. This study, published in the British Journal of Pharmacology, discovered that a class of drugs called opioid delta-receptor (DOP) agonists may help alleviate IBS symptoms by targeting the central nervous system rather than acting directly on the intestine.

One of the main motivations for this study was the growing evidence linking IBS closely to psychological stress. Saitoh’s group aimed to address this potential root cause by focusing on finding a novel animal model for this condition. In a 2022 study, they developed a mice model repeatedly exposed to psychological stress – using a method called chronic vicarious social defeat stress (cVSDS) – which developed symptoms similar to a type of IBS called IBS-D. These symptoms included overly active intestines and heightened sensitivity to abdominal pain, even though their organs showed no physical damage. The cVSDS animal model involved having the subject mouse repeatedly witness a territorial, aggressive mouse defeating a cage mate, inducing indirect chronic stress.

Using the cVSDS model, the researchers sought to determine whether DOP in the brain, which is closely linked to pain and mood regulation, could serve as promising drug targets for treating stress-induced IBS. To achieve this, they performed a series of detailed experiments to observe the effects of DOP agonists on IBS symptoms and chemical signaling in the brain. Some experiments involved measuring the speed of a charcoal meal through the intestine to assess gastrointestinal motility and evaluate the impact of stress or treatments on bowel movement speed, along with directly measuring neurotransmitter concentrations using in vivo brain microdialysis. This revealed that re-exposure to VSDS increased glutamate levels in the insular cortex, but these elevated levels were normalised with DOP agonists.

According to the results, the administration of DOP agonists helped relieve abdominal pain and regulated bowel movements in cVSDS mice. Interestingly, applying the DOP agonists directly to a specific brain region called the insular cortex had similar effects on IBS symptoms as systemic treatment. “Our findings demonstrated that DOP agonists acted directly on the central nervous system to improve diarrhoea-predominant IBS symptoms in mice, and suggest that the mechanism of action involves the regulation of glutamate neurotransmission in the insular cortex,” highlights Saitoh.

Taken together, the continued research by Saitoh’s group on this topic could pave the way for effective treatments for IBS. “DOP agonists could represent a groundbreaking new IBS treatment that not only improves IBS-like symptoms but also provides anti-stress and emotional regulation effects. In the future, we would like to conduct clinical developments with the goal of expanding the indication of DOP agonists for IBS, in addition to depression,” remarks Saitoh.

Compared to currently available IBS treatments, such as laxatives, antidiarrhoeals, analgesics, and antispasmodics, targeting the underlying stress with DOP agonists may offer a more definitive solution with minimal adverse effects. Further clarification of the roles of stress and brain chemistry in the development of IBS will be essential in achieving this much-needed medical breakthrough. With promising prospects, future studies will translate Saitoh’s group’s findings to humans, bringing great relief to those affected by IBS.

Source: Tokyo University of Science

Categories : Diet and Nutrition General InterestTags : Leave a comment

Slow Traffic Pushes Commuters to Choose Fast Food

On By ModernMedia
Photo by Why Kei on Unsplash

Ever notice how much more tempting it is to pick up fast food for dinner after being stuck in traffic? It’s not just you. New research shows that traffic delays significantly increase visits to fast food restaurants, leading to unhealthier eating.

“In our analysis focusing on Los Angeles County, unexpected traffic delays beyond the usual congestion led to a 1% increase in fast food visits. That might not sound like a lot, but it’s equivalent to 1.2 million more fast food visits per year in LA County alone. We describe our results as being modest but meaningful in terms of potential for changing unhealthy food choices,” said study author Becca Taylor, assistant professor at the University of Illinois Urbana-Champaign.

Taylor and her co-authors had access to more than two years’ of daily highway traffic patterns in Los Angeles, along with data showing how many cell phone users entered fast-food restaurants in the same time period.

With these data, the team created a computational model showing a causal link between unexpected traffic slow-downs and fast food visits. This pattern held at various time scales, including 24-hour cycles and by the hour throughout a given day. When analysed by the day, traffic delays of just 30 seconds per mile were enough to spike fast-food visits by 1%.

“It might not be intuitive to imagine what a 30-second delay per mile feels like,” Taylor said. “I think of it as the difference between 10a.m. traffic and 5p.m. traffic.”

When the researchers broke the day into hour-long segments, they found a significantly greater number of fast food visits when traffic delays hit during the evening rush hour. At the same time, grocery store visits declined slightly.

“If there’s traffic between 5 and 7p.m., which happens to be right around the evening meal time, we see an increase in fast food visits,” Taylor said.

“Drivers have to make a decision about whether to go home and cook something, stop at the grocery store first, or just get fast food.”

Considering every major city has both traffic and fast food restaurants lining highway feeder roads, it’s not a stretch to extrapolate the pattern beyond Los Angeles.

Taylor and her co-authors say the link between traffic and unhealthy food choices is just one more reason policymakers around the country and the globe should prioritize infrastructure reforms to ease congestion.

“Our results contribute to the literature suggesting time constraints are really important to the food choices people make. Any policies aimed at loosening time constraints – and traffic is essentially lost time – could help battle unhealthy eating,” Taylor said. “That could mean improvements in infrastructure to mitigate traffic congestion, expanding public transport availability, and potentially increasing work from home opportunities.”

Source: University of Illinois College of Agricultural, Consumer and Environmental Sciences

Categories : AgeingTags : Leave a comment

Omega-3s can Slow Down the Aging Process – Slightly

On By ModernMedia
Photo by Ravi Patel on Unsplash

Previous clinical studies have shown that a reduced calorie intake can slow down the aging process in humans. Taking vitamin D or omega-3 fatty acids has also shown promising results in slowing biological aging in animals. However, it was unclear whether these measures would also work in humans.

The therapies previously tested in the DO-HEALTH study led by Heike Bischoff-Ferrari are also associated with a slowing of the aging process. These showed that vitamin D and omega-3 fatty acids, as well as regular physical activity, reduce the risk of infections and falls, and prevent cancer and premature frailty. “These results inspired us to measure the direct influence of these three therapies on the biological aging process in the Swiss DO-HEALTH participants,” says Bischoff-Ferrari, professor of geriatrics and geriatric medicine at the University of Zurich.

Measuring biological and chronological age

One scientific approach to making biological aging measurable is the use of epigenetic clocks. They record chemical modifications of the DNA molecule, known as methylation, and thus quantify the difference between biological and chronological aging. The DO-HEALTH study has now for the first time investigated how sensitively this molecular biological measurement method reacts to targeted treatment.

The team led by Heike Bischoff-Ferrari, in collaboration with Steve Horvath, senior researcher at Altos Labs Cambridge (UK), who developed the watches, investigated the effect of omega-3s and/or vitamin D and/or simple strength training on biological aging in 777 people over the age of 70. Eight different treatment combinations were tested during the three-year study: subjects took 2000 international units (IU) of vitamin D and/or 1 gram of omega-3 fatty acids (from algae) daily and/or performed 30 minutes of strength training at home three times a week.

Biological age slowed down

When the researchers analysed the blood samples, they found that taking omega-3 fatty acids slowed down biological aging across several epigenetic clocks by up to four months – regardless of subjects’ gender, age or body mass index. The combination of omega-3, vitamin D and strength training proved to be even more effective, according to one of the four epigenetic clocks used.

“This result extends our previous findings from the DO-HEALTH study, in which these three factors combined had the greatest impact on reducing the risk of cancer and preventing premature frailty over a three-year period, to slowing down the biological aging process,” says Bischoff-Ferrari. Each of these measures works through different mechanisms that complement each other and, when combined, result in a heightened overall effect, according to the study author.

DO-HEALTH as a validation platform

At the same time, the research team draws attention to the limitations of the study. “There is no generally accepted gold standard for measuring biological age,” Bischoff-Ferrari explains. “However, we analysed the best currently validated epigenetic clocks, which reflect the state of the art.” To further advance the clinical application of biological clocks, Bischoff-Ferrari, together with leading international researchers in the Global Health Span Extension Consortium, plans to use DO-HEALTH and other global intervention studies as a validation platform for novel biomarkers of aging.

The researchers also point out that the sample consists exclusively of Swiss participants but will extend the trial to more countries.

Source: University of Zurich

Categories : CancerTags : Leave a comment

New Discovery Nips Childhood Brain Tumour in the Bud

On By ModernMedia
Credit: National Cancer Institute

Scientists at The Hospital for Sick Children (SickKids) have discovered a way to stop tumour growth before it starts for a subtype of medulloblastoma, the most common childhood malignant brain cancer.

Brain cancer presents a unique set of challenges for researchers – by the time a person experiences symptoms, the tumours are often so complex that the fundamental mechanisms driving the tumour growth are no longer easy to identify. A research team led by Dr Peter Dirks is working to combat this challenge for sonic hedgehog (SHH) medulloblastoma.

In a new study published in Nature Communications, the researchers identify that a protein is responsible for awakening ‘sleeping’ stem cells and driving SHH medulloblastoma tumour formation and regrowth. By blocking this protein and preventing the stem cells from waking, the study demonstrates what could be a pivotal treatment strategy for the cancer, utilising cutting-edge genomic approaches in combination with functional experiments in a preclinical model.

“Our findings offer a novel strategy to target cancer stem cells, providing hope for more effective treatments against aggressive brain tumours,” says Dirks, Senior Scientist in the Developmental, Stem Cell & Cancer Biology program and Chief of the Division of Neurosurgery.

Cancer interception in action

The research team began by examining cellular transitions that drove the development of SHH medulloblastoma tumours. They found that early in tumour development and after conventional treatments, a protein called OLIG2 would activate ‘sleeping’ stem cells, causing them to divide and grow into a tumour.

“There is order to how the cancer initiating stem cells undergo fate changes to form tumours. We can target an early transition event and intercept the entire process – essentially stopping the cancer in its earliest form,” says first author Dr Kinjal Desai, a postdoctoral researcher in the Dirks lab.

During these transitions, the researchers uncovered a key window during which tumour progression could be blocked. By combining a previously established treatment with a small molecule called CT-179, which disrupts the OLIG2 protein, the research team were able to target the residual stem cells left after treatment and prevent them from re-awakening, effectively preventing tumour relapse.

Similarly for early-stage SHH medulloblastoma, CT-179 prevented the tumour from forming and significantly increased survival rates in the preclinical model.

Together with additional preclinical models in a study published simultaneously in Nature Communications from colleagues at Children’s Healthcare of Atlanta and QIMR Berghofer Medical Research Institute in Australia, the findings showcase what could be an effective new treatment for SHH medulloblastoma, as well as other brain cancers including diffuse intrinsic pontine glioma (DIPG).

Model of proposed role of Olig2 and OLIG2 inhibition in tumour initiation and relapse; created in BioRender.com. Desai et al., Nat. Comm. 2024.

The study complements recent research from the Dirks Lab in Nature, which describes the early stages of glioblastoma development. While future research will expand these findings into clinical trials for patients, particularly among those being monitored for relapse, the Dirks lab, part of the Arthur and Sonia Labatt Brain Tumour Research Centre (BTRC), is excited for the diagnostic potential this discovery presents.

“At SickKids, we’re already genetically testing every child with cancer to inform their diagnosis and treatments – our study goes beyond genetic testing to precision biology,” says Dirks. “I am excited for a future where this ‘magic bullet’ for early treatment could be combined with diagnostic tests to potentially prevent the cancer from developing at all.”

Source: The Hospital for Sick Children

Categories : Obstetrics & GynaecologyTags : Leave a comment

Music Can Influence Foetal Heart Rate in the Womb

On By ModernMedia
Photo by Sergio Capuzzimati on Unsplash

Playing music has long been a way for expectant parents to connect with their children in the womb, but a group of researchers has found evidence it can calm foetal heart rates, potentially providing developmental benefits.

In the interdisciplinary journal Chaos, researchers studied the effect of classical music on a foetal heartbeat. The team used mathematical analysis tools to identify patterns in heart rate variability.

Typical measures of heart rate are an average of several beats across multiple seconds. In contrast, heart rate variability measures the time between individual beats. This measure can provide insight into the maturation of the foetal autonomic nervous system, with greater variability often indicating healthy development.

To test the effects music can have on foetal heart rate, the group of researchers recruited 36 pregnant women and played a pair of classical pieces for their foetuses. For the experiment, they chose “The Swan,” by French composer Camille Saint-Saëns, and “Arpa de Oro,” by Mexican composer Abundio Martínez.

By attaching external heart rate monitors, the researchers could measure the foetal heart rate response to both songs. And by employing nonlinear recurrence quantification analysis, they could identify changes in heart rate variability during and after the music was played.

“Overall, we discovered that exposure to music resulted in more stable and predictable foetal heart rate patterns,” said author Claudia Lerma. “We speculate that this momentary effect could stimulate the development of the foetal autonomic nervous system.”

In addition to the overall effects of playing music, the researchers looked at the differences between the two classical pieces. While both were effective, they found that the Mexican guitar melody had a stronger effect.

“When contrasting ‘The Swan’ with ‘Arpa de Oro,’ we did notice some significant differences,” said author Eric Alonso Abarca-Castro. “In particular, the second piece appeared to have a stronger impact on some measures, indicating that it produced heart rate patterns that were more predictable and regular. Factors like rhythmic characteristics, melodic structure, or cultural familiarity may be linked to this differentiation.”

For expectant parents at home, the researchers suggest that classical music could help promote fetal development.

“Our results suggest that these changes in foetal heart rate dynamics occur instantly in short-term fluctuations, so parents might want to consider exposing their foetuses to quiet music,” said Abarca-Castro. “Parents who play soothing music may stimulate and benefit the foetal autonomic system.”

The authors plan to continue to explore this effect, looking at different genres and types of music to further their understanding.

“To ascertain whether rhythmic or cultural variations elicit distinct foetal cardiac responses, we intend to increase the size of our sample and expand our investigation to include a variety of musical styles beyond classical pieces,” said author José Javier Reyes-Lagos.

Source: American Institute of Physics

Categories : OphthalmologyTags : Leave a comment

All in the Eyes: High Resolution Retinal Maps Aid Disease Diagnoses

On By ModernMedia
Photoreceptor cells in the retina. Credit: Scientific Animations

Researchers have conducted one of the largest eye studies in the world to reveal new insights into retinal thickness, highlighting its potential in the early detection of diseases like type 2 diabetes, dementia and multiple sclerosis.

The WEHI-led study, using cutting-edge artificial intelligence technology to analyse over 50 000 eyes from the UK Biobank, producing maps of the retina in unprecedented detail to better understand how retinal differences link to various diseases.

The findings, published in Nature Communications, open up new possibilities for using routine eyecare imaging as a tool to screen for and manage diseases, much like mammograms have for breast cancer.

Unlocking a window into the brain

The retina is part of the central nervous system, which also comprises the brain and spinal cord. Many diseases are linked to degeneration or disruption of this critical system, including neurodegenerative conditions such as dementia and metabolic disorders like diabetes.

Globally, neurological conditions alone are one of the leading causes of disability and illness, with over 3 billion people, or 43% of the world’s population living with a brain related condition.

Lead researcher, WEHI’s Dr Vicki Jackson, said the findings broaden the horizons for using retinal imaging as a doorway into the central nervous system, to help manage disease.

“We’ve shown that retinal imaging can act as a window to the brain, by detecting associations with neurological disorders like multiple sclerosis and many other conditions,” said Dr Jackson, a statistician and gene expert.

“Our maps’ fine-scale measurements reveal critical new details about connections between retinal thinning and a range of common conditions.”

The study also identified new genetic factors that influence retinal thickness, which are likely to play a role in the growth and development of a person’s retina.

“This research underscores the potential for retinal thickness to act as a diagnostic biomarker to aid in detecting and tracking the progression of numerous diseases. We can now pinpoint specific locations of the retina which show key changes in some diseases.”

The international research team, led by WEHI, applied AI methods to big population data of retinal imaging and compared information about each person’s genetics and health to reveal unprecedented links to disease.

The results created 50 000 maps with measurements at over 29 000 locations across the retina, identifying retinal thinning relating to 294 genes that play an important role in disease.

AI fast-tracking the diagnostic future

Study lead and bioinformatician, Professor Melanie Bahlo AM, said past studies had indicated correlations between retinal thickness and disease, but her team’s AI-powered discoveries shed deeper light on the complex spatial anatomy of the retina and its role in disease.

“Technologies like AI fuel discovery, and when fused with brilliant minds, there is an extraordinary ability to transform big population data into far-reaching insights,” Prof Bahlo, a lab head at WEHI, said.

“There has never been a time in history where this powerful combination — technology, big data and brilliant minds — has come together to advance human health.”

The research reinforces the growing field of oculomics (using the eye to diagnose health conditions) as an emerging, powerful and non-invasive approach for predicting and diagnosing diseases.

Source: Walter and Eliza Hall Institute

Categories : CancerTags : Leave a comment

Inhibitor Drugs to Treat Aggressive Breast Cancer Identified

On By ModernMedia
Colourised scanning electron micrograph of a breast cancer cell. Credit: NIH

A US study seeking more effective treatment for deadly metaplastic breast cancer has identified two inhibitor drugs with the potential to interrupt disease progression.

Houston Methodist and a team of researchers from across the country examined the biology of metaplastic breast cancer, comparing it to non-metaplastic triple negative breast cancer. They discovered metaplastic breast cancers typically exhibit two unique signaling pathways in their cell interaction. Researchers were able to disrupt these pathways using a class of inhibitors typically used to treat advanced cancers – phosphoinositide 3 kinase inhibitor (P13K) – in combination with a nitric oxide inhibitor (NOS) typically used to treat septic shock, cardiovascular disease and other conditions. When introduced to the cell, these drugs disrupted these pathways, making the treatment more effective.

A rare and aggressive form of disease, metaplastic breast cancer typically grows faster and is more likely to metastasise than other breast cancers. It is also more likely to recur after successful initial treatment. Patients with metaplastic breast cancer will often receive the same treatment as a patient with triple negative breast cancer, another aggressive and deadly form of the disease. However, metaplastic breast cancer often does not respond well.

The findings are published in Nature Communications The study’s corresponding author is Dr Jenny Chang, the executive vice president, president and CEO, and chief academic officer at the Houston Methodist Academic Institute.

“This is a significant finding because it offers a promising therapeutic option for one of the most aggressive and difficult-to-treat subtypes of breast cancer,” said Chang. “We have the potential to improve outcomes for patients who currently face limited treatment options and poor prognoses, marking an important step forward in cancer research and therapy.”

The first author, Dr Tejaswini Reddy, hopes these findings will help develop a specific care plan for metaplastic cancer patients and improve long-term survival of the disease.

“Our findings highlight a promising therapeutic combination that could hopefully change the landscape of metaplastic breast cancer treatment. Translating this research into a National Cancer Institute-funded clinical trial is crucial to improving outcomes for patients facing this rare and aggressive disease. Moreover, this approach may have broader implications, potentially benefiting patients with other cancers with similar biology,” said Reddy. 

The findings of this preclinical study have translated into a National Cancer Institute (NCI)-funded phase 2 clinical trial to help patients with this rare and aggressive malignancy (https://clinicaltrials.gov/study/NCT05660083).

Source: Houston Methodist

Categories : CancerTags : Leave a comment

Talking about HPV, Cervical Cancer and the HPV Vaccine

On By ModernMedia

As the Department of Health gears up for the first round of Human Papilloma Virus (HPV) vaccinations for girls between 9 and 14 from February 3 to March 28, we put the spotlight on HPV and cervical cancer. The focus is on: Empowering, Preventing and Early Detection of cervical cancer. It’s important because cervical cancer kills more South African adolescents and women aged 15 to 44 than any other cancer.  It can be successfully treated, if caught early enough but it’s far better to prevent it in the first place.

Dr Themba Hadebe, Clinical and Managed Care Executive at Bonitas, provides some insights and important information about cervical cancer – caused by persistent infection with HPV – why it is essential to screen for the virus and the vaccination that can help prevent it.

Why a vaccine against HPV?

HPV infects the cells of the cervix and, in some cases, the virus can persist – leading to abnormal changes in the cells that may eventually become cancerous. Over 99% of all cervical cancers are caused by persistent infection of high-risk types of HPV, including HPV-16 and HPV-18.

‘To help prevent cervical cancer, we have expanded our preventative care benefits to include the HPV vaccine across all plans,’ says Dr Hadebe.  ‘As recommended by The World Health Organization (WHO), this is 2 doses for females aged 9 to 14 years and 3 doses for females aged 15 to 26 years, per lifetime’.

Screening for HPV and cervical cancer: Screening is essential to mitigate the risk of developing cervical cancer and aims to identify cervical cell changes and detect early cervical cancers before they cause symptoms. Two screening tests help with detection:

  • Pap smear: Cervical cancer is usually a slow-growing cancer, which may not have immediate symptoms but can be found with regular pap smear tests (a procedure in which cells are scraped from the cervix and looked at under a microscope). The test looks for cell changes (pre-cancers) in the cervix that may progress to cancer if not treated.
  • HPV test: This test looks for the virus, particularly HPV-16 and HPV-18 that cause 90% of cervical cancers.

It is recommended that between the ages of 21 and 65, women should have a pap smear every two years and, from the age of 30 onwards, a pap smear and HPV test should be done every 5 years.

Signs and symptoms: The symptoms of the HPV virus can include: Lesions on the genital area as well as darker lesions on other parts of the body, to painful bumps on your upper limbs and skin growths on the balls of the feet and heels.

The power of prevention: ‘Talk to your daughter about important lifestyle choices she must make’, says Dr Hadebe. ‘These may be uncomfortable conversations to have but they’re vitally important to protect her from HPV and subsequent diseases.’ Discussion points include the fact that the HPV vaccination is her best opportunity for protection from the virus.  In addition, she needs to consider the following:

  • Delay having intercourse until she’s 18: The earlier she starts, the higher her risk of HPV infection
  • Use protection every time she is physically intimate: HPV is spread through skin-to-skin contact
  • Limit her number of intimate partners
  • Avoid smoking: Smoking damages the cells throughout the body, not just those in the lungs. Smoking not only increases her risk for cancer but it also increases her risk of dying from cancer, as well as from other diseases.
  • Maintain a healthy weight: The greater your body fat percentage, the higher the risk of cancer. Eating a nutritious, balanced diet and exercising regularly will help her manage her weight and strengthen her immune system.

If you develop cervical cancer: Just like other cancers, cervical cancer is graded according to severity. From in situ, which means it hasn’t spread to nearby tissue, through stage one (it’s still in the original organ and small).

If it progresses, it spreads to the surrounding lymph nodes and, in the most severe form, the cancer has metastasised to surrounding tissues and other lymph nodes.

As cervical cancer develops, the following may occur:

  • Abnormal bleeding, for example bleeding after sex
  • Pelvic pain unrelated to the menstrual cycle
  • Heavy or unusual discharge
  • Increased urinary frequency
  • Pain during urination

‘Cervical cancer is the most prevalent cancer among women after breast cancer,’ says Dr Hadebe. ‘Yet it has a good chance of being cured, if diagnosed at an early stage and treated promptly. Which is why, it’s important to have regular pap smears to detect any changes in the cervix and to vaccinate young girls to protect them against possible HPV infection.’

Additional information on cervical cancer and HPV can be found on the Bonitas website: www.bonitas.co.za or the Department of Health https://www.health.gov.za

Categories : Cancer IT in HealthcareTags : Leave a comment

AI Boosts Efficacy of Cancer Treatment, but Doctors Remain Key

On By ModernMedia
Photo by Tara Winstead on Pexels

A new study led by researchers from Moffitt Cancer Center, in collaboration with investigators from the University of Michigan,  shows that artificial intelligence (AI) can help doctors make better decisions when treating cancer. However, it also highlights challenges in how doctors and AI work together. The study, published in Nature Communications, focused on AI-assisted radiotherapy for non-small cell lung cancer and hepatocellular carcinoma.

Radiotherapy is a common treatment for cancer that uses high-energy radiation to kill or shrink tumors. The study looked at a treatment approach known as knowledge-based response-adaptive radiotherapy (KBR-ART). This method uses AI to optimize treatment outcomes by suggesting treatment adjustments based on how well the patient responds to the therapy.

The study found that when doctors used AI to help decide the best treatment plan, they made more consistent choices, reducing differences between doctors’ decisions. However, the technology didn’t always change doctors’ minds. In some cases, doctors disagreed with the AI suggested and made treatment decisions based on their experience and patient needs.

Doctors were asked to make treatment decisions for cancer patients, first without any technological assistance, and then with the help of AI. The AI system developed by the researchers uses patient data like medical imaging and test results to recommend changes in radiation doses. While some doctors found the suggestions helpful, others preferred to rely on their own judgment.

“While AI offers insights based on complex data, the human touch remains crucial in cancer care,” said Moffitt’s Issam El Naqa, PhD. “Every patient is unique, and doctors must make decisions based on both AI recommendations and their own clinical judgment.”

The researchers noted that while AI can be a helpful tool, doctors need to trust it for it to work well. Their study found that doctors were more likely to follow AI suggestions when they felt confident in its recommendations. “Our research shows that AI can be a powerful tool for doctors,” said Dipesh Niraula, PhD, an applied research scientist in Moffitt’s Machine Learning Department. “But it’s important to recognise that AI works best when it’s used as a support, not a replacement, for human expertise. Doctors bring their expertise and experience to the table, while AI provides data-driven insights. Together, they can make better treatment plans, but it requires trust and clear communication.”

The study’s authors hope that their findings can lead to better integration of AI tools and collaborative relationships that doctors can use to make more personalised treatment decisions for cancer patients. They also plan to further investigate how AI can support doctors in other medical fields.

Source: H. Lee Moffitt Cancer Center & Research Institute

Categories : Diet and Nutrition Obstetrics & GynaecologyTags : Leave a comment

The Importance of Vitamin D during First Trimester

On By ModernMedia
Photo by Michele Blackwell on Unsplash

Low vitamin D levels in the first trimester of pregnancy are associated with higher rates of preterm birth and decreased foetal length, according to a new study led by researchers in the Penn State Department of Nutritional Sciences. This research provides evidence that early pregnancy or even preconception may represent critical time points for intervening with women who have low vitamin D status, to optimise pregnancy outcomes.

Celeste Beck, who earned her doctorate in nutritional sciences from Penn State in 2023, and Alison Gernand, Beck’s doctoral adviser and associate professor of nutritional sciences at Penn State, led the study. Their results were recently published in The American Journal of Clinical Nutrition.

“More than 25% of women who are pregnant or lactating have lower than recommended levels of vitamin D,” Gernand said, explaining that prior research has demonstrated the effect of vitamin D on foetal skeletal growth, maternal immune function at the foetal interface, and the development of the placenta in pregnant women. “A lot of the development early in pregnancy requires vitamin D, so we conducted this study to better understand how early-pregnancy vitamin D status is related to pregnancy outcomes.”

Most prior studies on vitamin D status in pregnant women have measured vitamin D concentrations starting in the second trimester or later, the researchers said. The researchers said this study, to their knowledge, is the first to examine both first and second trimester maternal vitamin D status in relation to longitudinal foetal growth and pregnancy outcomes.

The researchers at Penn State partnered with colleagues at the University of Utah to test blood samples from 351 women collected as part of the Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-Be, which was funded by the National Institute of Child Health and Human Development and recruited pregnant women across the United States between 2010 and 2013.

According to the Institute of Medicine, less than 50nmol/L represents an insufficiency of vitamin D. When the researchers compared outcomes for women with vitamin D insufficiency (less than 50nmol/L) to women with sufficient vitamin D (more than or equal to 50nmol/L), they found no statistical differences in pregnancy outcomes. However, when the researchers compared pregnancy outcomes across a wider range of vitamin D concentrations, they found that pregnant women with first trimester vitamin D concentrations lower than 40 nmol/L were four times more likely to experience a preterm birth compared to women with vitamin D concentrations more than or equal to 80nmol/L.

Despite the higher risk of preterm birth in women with low vitamin D status, the researchers cautioned that these results were based on a very low number of preterm births in this study and recommend that additional, larger studies be conducted.

The researchers also observed an association between first-trimester vitamin D concentrations and certain foetal growth patterns. Women with higher levels of vitamin D experienced a small but statistically significant increase in foetal length.

Source: Penn State